{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy",
    "geneContextQualifier": "RET",
    "objectTherapeutic": "Selpercatinib [Retevmo]"
}